Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-102 SL Extension Study in PTSD
NCT03508700Phase 3Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Sep 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of Tonmya in post-traumatic stress disorder (PTSD), sponsored by Tonix Pharmaceuticals. Started Apr 2018; status: completed.
02
Drugs
Tonmya
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03508700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508700.